<DOC>
	<DOCNO>NCT01759888</DOCNO>
	<brief_summary>The primary objective protocol access utility 18F-DTBZ PET image vivo biomarker monitor neurodegeneration PD mouse model PD patient . Secondary , investigator analyze progression rate genetic-proving PARK8 PARK6 patient homogeneous phenotype genotype 18F-DTBZ PET imaging .</brief_summary>
	<brief_title>Development Novel 18F-DTBZ PET Imaging Biomarker Monitor Neurodegeneration PARK6 PARK8 Parkinsonism</brief_title>
	<detailed_description>Total 60 patient , 20 LRRK2 G2385R , 20 PARK6 , 20 idiopathic PD , recruit . Subjects evaluate sequentially 18F-DTBZ 36 month period . 18F-DTBZ PET scan perform twice , baseline , 24 ( 21~27 ) month follow start participation study . Subjects receive single i.v . administration approximately 10 mCi 18F-DTBZ immediately prior imaging . Whitney test use compare mean standard uptake value ratio ( SUVR ) value group . The decline rate VMAT2 density calculate compare SUVRs age-matched healthy subject previous study . Each evaluable subject involve study must fulfill inclusion exclusion criterion accord subject grouping , subject 3 visit scan ( total 6 visit study ) , one screening visit , one imaging visit , one safety evaluation visit . Safety measurement evaluate medical history , vital sign , physical examination , laboratory examination collect adverse event .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<criteria>1 . Both gender 20~80 year old . 2 . Written date informed consent self legal representative , obtain study procedure . 3 . Twenty PD patient prove carry LRRK2 G2385R mutation genetic laboratory . Patients n't mutation may contribute parkinsonism , LRRK2 G2019S , LRRK2 R1628P , PARK2 , PARK6 , SCA2 . 4 . Twenty PARK6 PD patient prove carry PINK1 mutation genetic laboratory . Patients n't mutation may contribute parkinsonism , LRRK2 , PARK2 , SCA2 . 5 . Twenty idiopathic PD patient prove carry known mutation , may contribute parkinsonism , LRRK2 , PARK2 , PARK6 , SCA2 . The age disease onset 50 year , know familial history parkinsonism spinocerebellar atrophy . 6 . All subject fulfil UK Parkinson 's Disease Society Brain Bank criterion `` possible '' `` probable '' PD . 1 . Pregnant become pregnant study current breast feeding . 2 . Any subject clinically significant abnormal laboratory value , and/or clinically significant unstable medical psychiatric illness . 1 . Clinically significant hepatic , renal , pulmonary , metabolic , endocrine disturbance , especially thyroid disease . 2 . Current clinically significant cardiovascular disease . ( cardiac surgery myocardial infarction within last 6 month ; unstable angina ; decompensated congestive heart failure ; significant cardiac arrhythmia ; congenital heart disease . 3 . History drug alcohol abuse within last year , prior prolonged hi story abuse . 4 . History presence QTc prolongation . 5 . History intracranial operation , include thalamotomy , pallidotomy , and/or deep brain stimulation . 6 . Any documented abnormality brain CT MRI brain , might contribute motor function , hydrocephalus , multiple infarction encephalomalacia , exclude . Mild cortical atrophy nonspecific white matter change allow . 7 . Any evidence secondary parkinsonism ( multiple infarct , intoxication , hydrocephalus , etc ) . 8 . General PET exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>